פוסט זה זמין גם ב:
עברית
TAKE-HOME MESSAGE
- In this multicenter retrospective cohort study, the authors compared the effects of standard-dose venous thromboembolism (VTE) prophylaxis with those of reduced-dose VTE prophylaxis in patients who are critically ill with a body weight of ≤50 kg. Although reduced-dose prophylaxis was associated with a significantly lower rate of composite bleeding, the rate of VTE was comparable in both the reduced-dose and standard-dose groups.
- Reduced-dose VTE prophylaxis has the potential to reduce the risk of bleeding without increasing the risk of VTE in critically ill patients with a low body weight.
ABSTRACT ![](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%20161%2060'%3E%3C/svg%3E)
Objective
To compare bleeding and thromboembolic events in low body weight patients receiving reduced-dose venous thromboembolism (VTE) prophylaxis versus standard-dose VTE prophylaxis.
Design
Multicenter, retrospective, cohort study.
Setting
Five Ascension Health Hospitals.
Patients
Adult, critically ill, low body weight (≤50 kg) patients who received either reduced-dose VTE prophylaxis (n = 140) or standard-dose VTE prophylaxis (n = 279) for at least 48 h.
Intervention
Reduced-dose prophylaxis (enoxaparin 30 mg daily or heparin 5000 units every 12 h subcutaneously) or standard-dose prophylaxis (enoxaparin 40 mg daily, enoxaparin 30 mg every 12 h, or heparin 5000 units every 8 h subcutaneously).
Measurements and Main Results
A total of 419 patients were included with a mean weight of 45.1 ± 4.2 kg in the standard-dose group and 44.0 ± 5.1 kg in the reduced-dose prophylaxis group (P = .02). The primary endpoint, composite bleeding, was significantly lower in patients receiving reduced-dose prophylaxis (5% vs 12.5%, P = .02). After adjusting for confounding factors, results remained consistent demonstrating reduced composite bleeding with reduced-dose prophylaxis (odds ratio: 0.36, 95% confidence interval: 0.14-0.96). Major bleeding events occurred in 3.6% of reduced-dose patients compared with 8.6% in standard-dose patients (P = .056). Clinically relevant nonmajor bleeding (5.4% vs 2.9%, P = .24) and VTE (2.2% vs 0%, P = .08) events were similar between groups.
Conclusions
A reduced-dose VTE prophylaxis strategy in low body weight, critically ill patients was associated with a lower risk of composite bleeding and similar rate of thromboembolism.